More and more its CMS (i.e., Medicare and Medicaid) or private insurance. Out-of-pocket spending for drugs is falling.
Source:
- Deloitte. “Value-based pricing for pharmaceuticals: Implications of the shift from volume to value” Issue Brief, 2012.
Unbiased Analysis of Today's Healthcare Issues
More and more its CMS (i.e., Medicare and Medicaid) or private insurance. Out-of-pocket spending for drugs is falling.
Source: